Crizotinib for Untreated Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

Lung, Respiratory and Thoracic CancerLymphoma

Crizotinib in patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer versus chemotherapy as a first-line treatment

BMC Cancer.

Zhou J, Zheng J, Zhang X, Zhao J, Zhu Y, Shen Q, Wang Y, Sun K, Zhang Z, Pan Z, Shen Y, Zhou J

doi: 10.1186/s12885-017-3720-8.

Lung, Respiratory and Thoracic Cancer

Phase 1/2 Study of the Safety and Tolerability of Nivolumab Plus Crizotinib for the First-Line Treatment of Anaplastic Lymphoma Kinase Translocation - Positive Advanced Non-Small Cell Lung Cancer (CheckMate 370)

J Thorac Oncol.

Spigel DR, Reynolds C, Waterhouse D, Garon EB, Chandler J, Babu S, Thurmes P, Spira A, Jotte R, Zhu J, Lin WH, Blumenschein G Jr.

doi: 10.1016/j.jtho.2018.02.022.

Lung, Respiratory and Thoracic CancerRadio-OncologyLymphoma

Alectinib versus crizotinib in treatment-naïve anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study

Ann Oncol.

Gadgeel S, Peters S, Mok T, Shaw AT, Kim DW, Ou SI, Pérol M, Wrona A, Novello S, Rosell R, Zeaiter A, Liu T, Nüesch E, Balas B, Camidge DR

doi: 10.1093/annonc/mdy405.

Lung Cancer

Molecular Diagnostic and Precision Medicine in Non-Small Cell Lung Cancer. An Update on the Treatment of the Most Important Actionable Oncogenic Driver Alterations.

1Department of Medical Oncology, University Hospital Basel, Basel, Switzerland.

Lung, Respiratory and Thoracic Cancer

Ensartinib vs Crizotinib for Patients With Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Randomized Clinical Trial

JAMA Oncol

Horn L, Wang Z, Wu G, Poddubskaya E, Mok T, Reck M, Wakelee H, Chiappori AA, Lee DH, Breder V, Orlov S, Cicin I, Cheng Y, Liu Y, Fan Y, Whisenant JG, Zhou Y, Oertel V, Harrow K, Liang C, Mao L, Selvaggi G, Wu YL

doi: 10.1001/jamaoncol.2021.3523

Lung, Respiratory and Thoracic CancerLymphoma

Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study

Ann Oncol.

Novello S, Mazières J, Oh IJ, de Castro J, Migliorino MR, Helland Å, Dziadziuszko R, Griesinger F, Kotb A, Zeaiter A, Cardona A, Balas B, Johannsdottir HK, Das-Gupta A, Wolf J

doi: 10.1093/annonc/mdy121.

Lung, Respiratory and Thoracic Cancer

Safety and Tolerability of Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer

Drug Saf.

Rocco D, Battiloro C, Della Gravara L, Gridelli C

doi: 10.1007/s40264-018-0771-y.

Lung, Respiratory and Thoracic CancerRadio-OncologyLymphoma

Exploratory Analysis of Brigatinib Activity in Patients With Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer and Brain Metastases in Two Clinical Trials

J Clin Oncol.

Camidge DR, Kim DW, Tiseo M, Langer CJ, Ahn MJ, Shaw AT, Huber RM, Hochmair MJ, Lee DH, Bazhenova LA, Gold KA, Ou SI, West HL, Reichmann W, Haney J, Clackson T, Kerstein D, Gettinger SN

doi: 10.1200/JCO.2017.77.5841.

Lung, Respiratory and Thoracic CancerLymphoma

Sequential therapy of crizotinib followed by alectinib for non-small cell lung cancer harbouring anaplastic lymphoma kinase rearrangement (WJOG9516L): A multicenter retrospective cohort study

Eur J Cancer

Ito K, Yamanaka T, Hayashi H, Hattori Y, Nishino K, Kobayashi H, Oya Y, Yokoyama T, Seto T, Azuma K, Fukui T, Kozuki T, Nakamura A, Tanaka K, Hirano K, Yokoi T, Daga H, Sakata S, Fujimoto D, Mori M, Maeno K, Aoki T, Tamura A, Miura S, Watanabe S, Akamatsu H, Hataji O, Suzuki K, Hontsu S, Azuma K, Bessho A, Kubo A, Okuno M, Nakagawa K, Yamamoto N

doi: 10.1016/j.ejca.2020.12.026

Related content

Crizotinib in patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer versus chemotherapy as a first-line treatment

Phase 1/2 Study of the Safety and Tolerability of Nivolumab Plus Crizotinib for the First-Line Treatment of Anaplastic Lymphoma Kinase Translocation - Positive Advanced Non-Small Cell Lung Cancer (CheckMate 370)

Alectinib versus crizotinib in treatment-naïve anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study

Molecular Diagnostic and Precision Medicine in Non-Small Cell Lung Cancer. An Update on the Treatment of the Most Important Actionable Oncogenic Driver Alterations.

Ensartinib vs Crizotinib for Patients With Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Randomized Clinical Trial

Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study

Safety and Tolerability of Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer

Exploratory Analysis of Brigatinib Activity in Patients With Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer and Brain Metastases in Two Clinical Trials

Sequential therapy of crizotinib followed by alectinib for non-small cell lung cancer harbouring anaplastic lymphoma kinase rearrangement (WJOG9516L): A multicenter retrospective cohort study